Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption
Condition(s):Migraine; Headache, MigraineLast Updated:September 22, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Migraine; Headache, MigraineLast Updated:September 22, 2023Recruiting
Condition(s):Atopic DermatitisLast Updated:February 23, 2024Recruiting
Condition(s):NSCLC Stage IVLast Updated:February 22, 2024Recruiting
Condition(s):Non-Malignant NeoplasmLast Updated:December 4, 2023Recruiting
Condition(s):Immunological Pure Red Cell AplasiaLast Updated:September 29, 2022Not yet recruiting
Condition(s):Multiple Cancer; Colorectal CancerLast Updated:February 7, 2024Recruiting
Condition(s):Mild Alzheimer’s Disease; Mild Cognitive Impairment (MCI) Due to Alzheimer’s DiseaseLast Updated:September 28, 2023Recruiting
Condition(s):LymphomaLast Updated:March 20, 2024Recruiting
Condition(s):Chronic Rhino-sinusitis; IL-4R; Monoclonal Antibody; BiomarkerLast Updated:June 23, 2022Not yet recruiting
Condition(s):Acute GoutLast Updated:December 14, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.